Fc fusion protein of long-acting recombinant human growth hormone
A fusion protein, hgh-l-vfc technology, applied in the fields of molecular biology and medicine, can solve the problems of no half-life GH derivatives, difficulties in the construction of hGH-L-vFc fusion protein and the like
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0081] Example 1 Construction of encoding hGH-L-vFc γ2 gene encoding fusion protein
[0082] 1. Preparation of the gene sequence plasmid containing human-growth hormone
[0083] hGH-L-vFc γ2 The fusion protein coding sequence is composed of several DNA fragments. The preparation of the gene encoding the leader peptide and mature protein of human GH was prepared by artificial synthesis according to the gene sequence of human-growth hormone contained in the NCBI reference number NM_000515.3. The synthesis method is to first proceed along the double-stranded DNA sequence of the hGH gene from the 5' terminal to the 3' terminal to prepare four oligonucleotide fragments with alternating upper and lower chains and a length of about 180 bases. The terminal end of each fragment contains approximately 20 bases of complementary overlapping sequence with the terminal end of the next complementary strand fragment, respectively. Then, the four oligonucleotide fragments were combined int...
Embodiment 2
[0096] Example 2 Construction of encoding hGH-L-vFc γ4 gene encoding fusion protein
[0097] Due to dissociation of the inter-heavy chain disulfide bonds in the hinge region, a portion of human IgG4 dissociates to form a molecule considered to be a half-antibody. This situation does not normally occur in the other three human IgG isotype molecules. The literature shows that the 228 position in IgG1 and IgG2 is Pro, while in IgG4 this position is Ser228. A single amino acid substitution of the Ser228 residue of IgG4 with Pro allows IgG4 to remain intact as an antibody molecule (see Angal et al., Molec. Immunol., 30: 105-108, 1993; Owens et al., Immunotechnology, 3: 107-116, 1997; US Patent No. 6,204,007). In addition, the Fc γ4 Mutation of Leu235Ala can make this Fc γ4 Variants have reduced binding to FcγRs. This mutation, together with the aforementioned Ser228Pro mutation, will allow the fusion protein to be purified in a more uniform and complete preparation.
[0098]...
Embodiment 3
[0102] Example 3 Construction of encoding hGH-L-vFc γ1 gene encoding fusion protein
[0103]The hinge region of a human IgG1 heavy chain contains 15 amino acid residues including 3 cysteines (GluProLysSerCysAspLysThrHisThrCysProProCysPro). Among these three cysteine residues, the second and third are involved in the formation of disulfide bonds between the two heavy chains. The first cysteine residue is involved in disulfide bonding with the IgG light chain. Since there is no light chain in the Fc fusion protein molecule, this cysteine residue may pair with other cysteine residues, resulting in nonspecific disulfide bonding. To prevent this non-specific disulfide bonding, the Fc γ1 The hinge region was shortened to eliminate the first cysteine residue (AspLysThrHisThrCysProProCysPro). Fc-containing primers were obtained by reverse transcription and PCR using RNA prepared from human leukocytes and appropriate 5' primers (SEQ ID NO: 13) and 3' primers (SEQ ID NO: 4...
PUM
Property | Measurement | Unit |
---|---|---|
molecular weight | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com